A marine macrolide with diverse biological activities
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bryostatin 1

Item No. 14802

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E,4E)-2,4-octadienoic acid ester
CAS Number
83314-01-6
Synonyms
  • NSC 339555
Molecular Formula
C47H68O17
Formula Weight
905.0
Purity
≥98%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
DMSO: 25 mg/mlEthanol: 25 mg/ml
SMILES
O[C@](O[C@@](C[C@](OC(C[C@@H](C[C@@](C1)([H])O2)O)=O)([H])[C@H](O)C)([H])C/C3=C\C(OC)=O)(C(C)(/C=C/[C@](C/C4=C\C(OC)=O)([H])O[C@](C4)([H])C[C@]2(C(C)([C@H]1OC(C)=O)C)O)C)[C@H]3OC(/C=C/C=C/CCC)=O
InChi Code
InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1
InChi Key
MJQUEDHRCUIRLF-TVIXENOKSA-N
Origin
Animal/Bugula neritina
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 µg

    $655

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Bryostatin 1 is a marine macrolide that has been found in B. neritina and has diverse biological activities.1,2,3,4,5 It binds to PKCα, PKCβ1, PKCγ, PKCδ, PKCε, PKCη, and PKCθ (Kis = 0.8-3.0 nM) and induces PKC activation or inhibition in cancer cells in a concentration-dependent manner.1,2 Bryostatin 1 (50 nM) reduces the production of IL-2 and increases the production of IL-10 in LPS-stimulated mouse bone marrow-derived dendritic cells (BMDCs).1 It decreases cell surface levels of CD4 and chemokine (C-C motif) receptor 5 (CCR5) and reduces HIV-1 infectivity in isolated human monocyte-derived macrophages.3 In vivo, bryostatin 1 (30 µg/kg) reduces spinal cord and brain T cell infiltration and disease severity in a mouse model of experimental autoimmune encephalomyelitis (EAE).4 It also decreases blast-induced increases in blood-brain barrier (BBB) permeability in a rat model of traumatic brain injury (TBI) when administered at a dose of 2.5 mg/kg.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Abramson, E., Hardman, C., Shimizu, A.J., et al. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation. Cell. Chem. Biol. 28(4), 537-545 (2021).

    2. Kortmansky, J., and Schwartz, G.K. Bryostatin-1: A novel PKC inhibitor in clinical development. Cancer Invest. 21(6), 924-936 (2003).

    3. Hany, L., Turmel, M.-O., Barat, C., et al. Bryostatin-1 decreases HIV-1 infection and viral production in human primary macrophages. J. Virol. 96(4), e0195321 (2022).

    4. Kornberg, M.D., Smith, M.D., Shirazi, H.A., et al. Bryostatin-1 alleviates experimental multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 115(9), 2186-2191 (2018).

    5. Lucke-Wold, B.P., Logsdon, A.F., Smith, K.E., et al. Bryostatin-1 restores blood brain barrier integrity following blast-induced traumatic brain injury. Mol. Neurobiol. 52(3), 1119-1134 (2015).